Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Fineline Cube Apr 20, 2026
Company Deals

Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463

Fineline Cube Jan 14, 2025

US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly...

Company Deals

Cornerstone Robotics Raises $68.2M in Series C to Advance Surgical Robots

Fineline Cube Jan 14, 2025

Cornerstone Robotics, an innovative surgical robot developer based in Shenzhen, has reportedly raised over RMB...

Company Medical Device

MGI Tech’s DNBSEQ-E25 Receives NMPA License as World’s First Self-Luminescent Sequencer

Fineline Cube Jan 14, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd has announced that it has received a...

Company Medical Device

Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment

Fineline Cube Jan 14, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark...

Company Deals

Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline

Fineline Cube Jan 14, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100%...

Company Drug

Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA

Fineline Cube Jan 14, 2025

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...

Company Drug

Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China

Fineline Cube Jan 14, 2025

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...

Company Drug

Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors

Fineline Cube Jan 14, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals Drug

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ

Fineline Cube Jan 14, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with...

Company Drug

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...

Company Deals

Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices

Fineline Cube Jan 14, 2025

Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices...

Company Deals

MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors

Fineline Cube Jan 14, 2025

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...

Company Deals

Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500

Fineline Cube Jan 14, 2025

China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...

Company Drug

CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment

Fineline Cube Jan 14, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...

Company Deals

3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303

Fineline Cube Jan 14, 2025

China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...

Company Deals Medical Device

CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion

Fineline Cube Jan 14, 2025

CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...

Company Drug

JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE

Fineline Cube Jan 13, 2025

China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...

Company Drug

CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval

Fineline Cube Jan 13, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...

Company Deals

Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership

Fineline Cube Jan 13, 2025

China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...

Company Medical Device

Johnson & Johnson MedTech’s Dual Energy Catheter Gains CE Mark

Fineline Cube Jan 13, 2025

US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF...

Posts pagination

1 … 215 216 217 … 654

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
  • Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.